KCNN4 — Drug Target

All drugs that target KCNN4 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Sodium-activated potassium channel inhibitor · sodium-activated potassium channel inhibitor

Phase 3 pipeline (2)

• TELMINUVO Tab. (80/2.5mg) · Chong Kun Dang Pharmaceutical · Sodium-activated potassium channel inhibitor · Cardiovascular
  Telminuvo is a selective inhibitor of the sodium-activated potassium channel, KCNN4.
• TEV-56248 · Teva Branded Pharmaceutical Products R&D, Inc. · sodium-activated potassium channel inhibitor · Neurology
  TEV-56248 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.

Phase 2 pipeline (3)

• CHF 5259 · Chiesi Farmaceutici S.p.A. · Sodium-activated potassium channel inhibitor · Cardiovascular
  CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.
• AN2690, 2.5% · Pfizer · sodium-activated potassium channel inhibitor · Neurology
  AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.
• AN2690 · Pfizer · Sodium-activated potassium channel inhibitor · Neurology
  AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.